GenFleet Therapeutics-B (02595) announces the publication arrangements for clinical study data related to GFH375 and GFH276.

Zhitong Finance APP News, GenFleet Therapeutics-B (02595) announced that the company will hold an online investor conference on October 15, 2026, to release preliminary research data on its investigational product GFH375 (KRAS G12D inhibitor) in combination with cetuximab for the treatment of KRAS G12D-mutant solid tumors.